D

DreamCIS Inc
KOSDAQ:223250

Watchlist Manager
DreamCIS Inc
KOSDAQ:223250
Watchlist
Price: 5 470 KRW 14.08% Market Closed
Market Cap: ₩134.5B

DreamCIS Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

DreamCIS Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
D
DreamCIS Inc
KOSDAQ:223250
Inventory
₩339m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Inventory
₩3.1T
CAGR 3-Years
10%
CAGR 5-Years
37%
CAGR 10-Years
N/A
A
ADM Korea Inc
KOSDAQ:187660
Inventory
₩0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
Peptron Inc
KOSDAQ:087010
Inventory
₩239.8m
CAGR 3-Years
6%
CAGR 5-Years
-4%
CAGR 10-Years
20%
S
ST Pharm Co Ltd
KOSDAQ:237690
Inventory
₩163.1B
CAGR 3-Years
11%
CAGR 5-Years
22%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Inventory
₩160.7m
CAGR 3-Years
-7%
CAGR 5-Years
8%
CAGR 10-Years
N/A
No Stocks Found

DreamCIS Inc
Glance View

DreamCIS, Inc. operates as clinical trial agency which engages in the provision of clinical online information and consultation services. The company is headquartered in Seoul, Seoul. The company went IPO on 2020-05-22. The firm mainly provides services include regulatory post-marketing surveillance (rPMS), clinical trial, non-interventional study (NIS) and others. The firm provides its services within domestic market and to overseas markets.

Intrinsic Value
6 975.09 KRW
Undervaluation 22%
Intrinsic Value
Price
D

See Also

What is DreamCIS Inc's Inventory?
Inventory
339m KRW

Based on the financial report for Dec 31, 2024, DreamCIS Inc's Inventory amounts to 339m KRW.

What is DreamCIS Inc's Inventory growth rate?
Inventory CAGR 1Y
-47%

Over the last year, the Inventory growth was -47%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett